Add the following claims:

--88. (new) A method of determining the presence or absence of dysplastic or neoplastic cells in a test sample from an individual, the method comprising:

contacting the test sample with an antibody or antibody fragment directed against Minichromosome Maintenance protein 2 (MCM2 protein); and

determining amount and/or pattern of binding of said antibody or antibody fragment to said test sample;

whereby an increase in said amount and/or a difference in said pattern if detected for the test sample compared with normal is indicative of presence of dysplastic or neoplastic cells in said test sample.

89. (new) A method according to claim 88 wherein binding of said antibody or antibody fragment to MCM2 protein in the test sample is indicative of the presence of dysplastic or neoplastic cells in said test sample.

90. (new) A method according to claim 88 wherein a difference in pattern of binding of said antibody or antibody fragment to said test sample compared with normal is indicative of the presence of dysplastic or neoplastic cells in said test sample.

91. (new) A method according to claim 88 wherein a sample of tissue is tested.

92. (new) A method according to claim 91 wherein the sample of tissue is fresh or frozen.

93. (new) A method according to claim 91 wherein the sample of tissue is not formalin fixed or paraffin embedded.

Sub C1

94. (new) A method according to claim 91 wherein the sample of tissue is not the subject of antigen retrieval or pressure cooking/autoclaving.

95. (new) A method according to claim 91 wherein the tissue is selected from lung, breast, colon, prostate, stomach, skin, oesophagus and bladder.

96. (new) A method according to claim 92 wherein the tissue is selected from lung, breast, colon, prostate, stomach, skin, oesophagus and bladder.

97. (new) A method according to claim 93 wherein the tissue is selected from lung, breast, colon, prostate, stomach, skin, oesophagus and bladder.

98. (new) A method according to claim 91 wherein the tissue is breast tissue.

99. (new) A method according to claim 92 wherein the tissue is breast tissue.

100. (new) A method according to claim 88 wherein a sample of cells is tested.

101. (new) A method according to claim 88 wherein the sample is provided from fluid taken from the individual.

102. (new) A method according to claim 101 wherein a sample of cells is provided from said fluid.

Sub C1

103. (new) A method according to claim 101 wherein the fluid is blood.

104. (new) A method according to claim 101 wherein the fluid is urine.

105. (new) A method according to claim 88 wherein a population of individuals is screened.

106. (new) A method of determining the presence or absence of dysplastic or neoplastic cells in a test cervical sample from an individual, the method comprising:

contacting the test cervical sample with an antibody or antibody fragment directed against Minichromosome Maintenance protein 2 (MCM2); and

determining an amount and/or pattern of binding of said antibody or antibody fragment to said test cervical sample;

whereby an increase in said amount and/or a difference in said pattern if detected for the test cervical sample compared with normal is indicative of presence of dysplastic or neoplastic cells in said test cervical sample.

Sub C1

107. (new) A method according to claim 106 wherein the sample is a cervical smear.

108. (new) A method according to claim 107 wherein binding of said antibody or antibody fragment to MCM2 protein in the cervical smear is indicative of the presence of dysplastic or neoplastic cells in said cervical smear.

109. (new) A method according to claim 106 wherein a population of individuals is screened.--

Add C1

REMARKS

Claims 1-87 have been canceled, without prejudice.

Claims 88-109 have been added and are pending.

The specification has been amended, as provided in the parent application Serial No. 09/175,947. No new matter has been added.

The specification has been amended to include the attached Sequence Listing. The attached paper copy of the Sequence Listing is the same as the paper and computer-readable copies of the Sequence Listing filed in the parent application Serial No. 09/175,947. The Office is requested to use the computer-readable copy of the